Emergent BioSolutions (EBS) Cash from Operations Growth (1y) (2011 - 2026)
Emergent BioSolutions (EBS) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.46% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 425.00% |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | -201.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -201.79% |
| Dec 31, 2025 | 197.25% |
| Sep 30, 2025 | -101.50% |
| Jun 30, 2025 | 124.00% |
| Mar 31, 2025 | 82.11% |
| Dec 31, 2024 | -348.91% |
| Sep 30, 2024 | 156.17% |
| Jun 30, 2024 | 141.52% |
| Mar 31, 2024 | 65.98% |
| Dec 31, 2023 | -65.41% |
| Sep 30, 2023 | 181.08% |
| Jun 30, 2023 | -633.33% |
| Mar 31, 2023 | -393.30% |
| Dec 31, 2022 | -71.72% |
| Sep 30, 2022 | -543.11% |
| Jun 30, 2022 | 47.47% |
| Mar 31, 2022 | -831.37% |
| Dec 31, 2021 | 33.37% |
| Sep 30, 2021 | -84.13% |
| Jun 30, 2021 | -123.22% |